Table 3. Retrospective studies comparing... | American Society of Hematology

Table 3.

Retrospective studies comparing thrombosis recurrence and major bleeding in MPN patients receiving VKA or DOAC

Reference	Study population	N on VKA	N on DOAC	Overall thrombotic recurrence		VTE recurrence		Major bleeding		Median follow-up (years)
Reference	Study population	N on VKA	N on DOAC	VKA	DOAC	VKA	DOAC	VKA	DOAC	Median follow-up (years)
Huenerbein et al²⁹	PV/ET/PMF/ MPN-U on systemic anticoagulation for VTE or ATE	45	26	48.8%	15.3%	24.4%	11.5%	8.88%	7.6%	3.2
Fedorov et al³⁰	PV/ET/PMF/ MPN-U on systemic anticoagulation for VTE or ATE	31	22	19.4%	22.7%	—	—	6.4%	4.5%	1.2

Reference	Study population	N on VKA	N on DOAC	Overall thrombotic recurrence		VTE recurrence		Major bleeding		Median follow-up (years)
Reference	Study population	N on VKA	N on DOAC	VKA	DOAC	VKA	DOAC	VKA	DOAC	Median follow-up (years)
Huenerbein et al²⁹	PV/ET/PMF/ MPN-U on systemic anticoagulation for VTE or ATE	45	26	48.8%	15.3%	24.4%	11.5%	8.88%	7.6%	3.2
Fedorov et al³⁰	PV/ET/PMF/ MPN-U on systemic anticoagulation for VTE or ATE	31	22	19.4%	22.7%	—	—	6.4%	4.5%	1.2

MPN-U, myeloproliferative neoplasm-unclassifiable: PV, plycythemia vera.